tbuckley/cabot-search huggingface dataset:
Employment Outcomes of Men Treated for Prostate Cancer
Authors: Cathy J. Bradley, David Neumark, Zhehui Luo, Heather Bednarek, Maryjean Schenk
Journal: JNCI Journal of the National Cancer Institute (2005)

Some organizations recommend prostate cancer screening for men younger than age 65 years, many of whom will be employed when they are diagnosed and treated for prostate cancer. Yet little is known about how prostate cancer and its treatment affect men's employment status. Consequently, we explored employment outcomes 6 and 12 months after the diagnosis of prostate cancer.We collected data from a prospective, population-based, longitudinal cohort of 267 men aged 30-65 years who had been diagnosed with prostate cancer and compared their likelihood of employment to that of men in two population-based control groups of 283 and 256 men without prostate cancer. The study outcomes were, among all participants, employment status and, among patients with prostate cancer, reasons why they remained employed, reasons why their weekly hours worked changed, and work-related disabilities. We predicted employment using probit regression models. In addition, we tested differences between the samples with two-sample Wilcoxon rank sum tests and chi-square tests. All statistical tests were two-sided.Patients with prostate cancer were 10 percentage points (95% confidence interval [CI] = 2.50 to 17.51 percentage points; P = .009) less likely to be working 6 months after their diagnosis than men without prostate cancer. However, at 12 months after diagnosis, the likelihood of employment for prostate cancer patients and control subjects was not statistically significantly different (P = .771). Some patients reported that cancer and its treatment interfered with their ability to perform physical and cognitive tasks at work 12 months after diagnosis. For example, 26% (95% CI = 18.51% to 33.87%) of men (33 patients) reported that cancer interfered with their ability to perform tasks that involved physical effort.Prostate cancer and its treatment appear to have an impact on employment.
A comparative study of vicilin genes in Lens: negative evidence of concerted evolution
Authors: L. E. Saenz de Miera, M. Perez de la Vega
Journal: Molecular Biology and Evolution (1998)

Genes for vicilin, a component of legume seed storage proteins, have been identified in the cultivated lentil (Lens culinaris ssp. culinaris) and in wild species of the genus Lens. Five different types of vicilin sequences (designated A-E) have been identified in each lentil individual. The different types of sequences, and some possible variants of them (also present in each individual) are part of the vicilin family of genes. Type D sequences have the characteristics of nonprocessed pseudogenes. Comparison of nucleotide sequences indicates that lentil vicilin sequences are similar to vicilin sequences of other legume species, in particular to those of the tribe Vicieae, in which the genes Lens is included. Sequence comparison and distance and parsimony trees indicated that two groups or subfamilies of sequences, including, respectively, types A, B, and E (47 kDa vicilins) and types C and D (50 kDa), can be distinguished in lentil and other Vicieae species, and that in the Vicieae species there is no evidence of concerted evolution among the vicilin sequences of different gene subfamilies or sequences groups, as has been suggested for other legume species.
MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity
Authors: Jing Jing Li, Hock L. Tay, Steven Maltby, Yang Xiang, Fiona Eyers, Luke Hatchwell, Hong Zhou, Hamish D. Toop, Jonathan C. Morris, Parameswaran Nair, Joerg Mattes, Paul S. Foster, Ming Yang
Journal: Journal of Allergy and Clinical Immunology (2015)
Is Migraine a Progressive Brain Disease?
Authors: Richard B. Lipton, Jullie Pan
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Destructive T cells lured by lipids
Authors: Heather L. Van Epps
Journal: The Journal of Experimental Medicine (2005)

T cells that are drawn to the airways by leukotrienes attack lung tissue and contribute to transplant rejection, according to Medoff and colleagues on page 97. Mice lacking the leukotriene receptor BLT1 were protected from lethal T cell attack. The authors thus suggest that drugs designed to block this receptor may have therapeutic potential in patients who develop a lethal complication of lung transplant called obliterative bronchiolitis.

T cell recruitment to sites of inflammation has traditionally been thought to depend primarily on the interaction between chemotactic peptides (chemokines), produced by cells in the inflamed tissue, and their corresponding receptors on T cells. However, chemotactic lipid mediators such as leukotrienes and prostaglandins—known for attracting neutrophils and eosinophils—have recently been shown to contribute to T cell recruitment. Early lung invasion by T cells in response to an inhaled allergen was blunted in mice lacking the leukotriene B4 (LTB4) receptor BLT1. But this decrease did not persist, calling into question the significance of leukotriene-induced T cell migration in disease.






Figure 

Inflammation within the tracheal lumen (asterisks) after allogeneic tracheal transplantation is decreased in the absence of the leukotriene receptor BLT1 (right).




Medoff and colleagues now show that BLT1-deficient mice were less likely to develop T cell-mediated airway obstruction following allogeneic tracheal transplantation, demonstrating that leukotriene-induced T cell migration contributes to disease. This finding is consistent with previous studies showing that inhibition of BLT1 signaling was protective in other mouse models of allogeneic transplantation. However the contribution of T cell trafficking was never evaluated in those models.

Elimination of BLT1 did not completely reverse T cell infiltration into the lung, suggesting that LTB4 does not act alone. The authors suggest that chemokines may also contribute to the T cell recruitment—a possibility they are currently investigating.
Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity
Authors: Yun Chen, Yao Guo, Jiayu Han, Wanting Tina Ho, Shibo Li, Xueqi Fu, Zhizhuang Joe Zhao
Journal: Journal of Hematology & Oncology (2012)

Gain-of-function mutations of tyrosine kinase FLT3 are frequently found in acute myeloid leukemia (AML). This has made FLT3 an important marker for disease diagnosis and a highly attractive target for therapeutic drug development. This study is intended to generate a sensitive substrate for assays of the FLT3 enzymatic activity.We expressed in Escherichia coli cells a glutathione S-transferase (GST) fusion protein designated GST-FLT3S, which contains a peptide sequence derived from an autophosphorylation site of FLT3. The protein was used to analyze tyrosine kinase activity of baculovirus-expressed FLT3 and crude cell extracts of bone marrow cells from AML patients. It was also employed to perform FLT3 kinase assays for FLT3 inhibitor screening.GST-FLT3S in solution or on beads was strongly phosphorylated by recombinant proteins carrying the catalytic domain of wild type FLT3 and FLT3D835 mutants, with the latter exhibiting much higher activity and efficiency. GST-FLT3S was also able to detect elevated tyrosine kinase activity in bone marrow cell extracts from AML patients. A small-scale inhibitor screening led to identification of several potent inhibitors of wild type and mutant forms of FLT3.GST-FLT3S is a sensitive protein substrate for FLT3 assays. It may find applications in diagnosis of diseases related to abnormal FLT3 activity and in inhibitor screening for drug development.
Serum 2 microglobulin correlates with the new ESSDAI in patients with Sjogren's syndrome
Authors: M. Pertovaara, M. Korpela
Journal: Annals of the Rheumatic Diseases (2011)

<h3>Abstract</h3> Ticks are arthropod vectors of pathogens of both Veterinary and Public health importance. Ticks are largely controlled by acaricide application. However, acaricide efficacy is hampered by high cost, the need for regular application and selection of multi-acaricide resistant tick populations. In light of this, future tick control approaches are poised to rely on integration of rational acaricide application and other methods such as vaccination. To contribute to systematic research-guided efforts to produce anti-tick vaccines, we carried out an <i>in silico</i> tick Aquaporin-1 protein (AQP1) analysis to identify unique tick AQP1 peptide motifs that can be used in future peptide anti-tick vaccine development. We used multiple sequence alignment (MSA), motif analysis, homology modeling, and structural analysis to identify unique tick AQP1 peptide motifs. BepiPred, Chou &amp; Fasman-Turn, Karplus &amp; Schulz Flexibility and Parker-Hydrophilicity prediction models were used to asses these motifs’ abilities to induce antibody mediated immune responses. Tick AQP1 (MK334178) protein homology was largely similar to the bovine AQP1 (PDB:1J4N) (23% sequence similarity; Structural superimposition RMS=1.475). The highest similarities were observed in the transmembrane domains while differences were observed in the extra and intra cellular protein loops. Two unique tick AQP1 (MK334178) motifs, M7 (residues 106-125, <i>p</i>=5.4e-25) and M8 (residues 85-104, <i>p</i>=3.3e-24) were identified. These two motifs are located on the extra-cellular AQP1 domain and showed the highest Parker-Hydrophilicity prediction immunogenic scores of 1.153 and 2.612 respectively. The M7 and M8 motifs are a good starting point for the development of potential peptide-based anti-tick vaccine. Further analyses such as <i>in vivo</i> immunization assays are required to validate these findings.
Common variants in KCNN3 are associated with lone atrial fibrillation
Authors: Patrick T Ellinor, Kathryn L Lunetta, Nicole L Glazer, Arne Pfeufer, Alvaro Alonso, Mina K Chung, Moritz F Sinner, Paul I W de Bakker, Martina Mueller, Steven A Lubitz, Ervin Fox, Dawood Darbar, Nicholas L Smith, Jonathan D Smith, Renate B Schnabel, Elsayed Z Soliman, Kenneth M Rice, David R Van Wagoner, Britt-M Beckmann, Charlotte van Noord, Ke Wang, Georg B Ehret, Jerome I Rotter, Stanley L Hazen, Gerhard Steinbeck, Albert V Smith, Lenore J Launer, Tamara B Harris, Seiko Makino, Mari Nelis, David J Milan, Siegfried Perz, Tõnu Esko, Anna Köttgen, Susanne Moebus, Christopher Newton-Cheh, Man Li, Stefan Möhlenkamp, Thomas J Wang, W H Linda Kao, Ramachandran S Vasan, Markus M Nöthen, Calum A MacRae, Bruno H Ch Stricker, Albert Hofman, André G Uitterlinden, Daniel Levy, Eric Boerwinkle, Andres Metspalu, Eric J Topol, Aravinda Chakravarti, Vilmundur Gudnason, Bruce M Psaty, Dan M Roden, Thomas Meitinger, H-Erich Wichmann, Jacqueline C M Witteman, John Barnard, Dan E Arking, Emelia J Benjamin, Susan R Heckbert, Stefan Kääb
Journal: Nature Genetics (2010)
Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease
Authors: Hanna Gazda, Jeffrey M. Lipton, Thiébaut Noël Willig, Sarah Ball, Charlotte M. Niemeyer, Gil Tchernia, Narla Mohandas, Mark J. Daly, Anna Ploszynska, Karen A. Orfali, Adrianna Vlachos, Bertil E. Glader, Roma Rokicka-Milewska, Akira Ohara, David Baker, Dagmar Pospisilova, Allison Webber, David H. Viskochil, David G. Nathan, Alan H. Beggs, Colin A. Sieff
Journal: Blood (2001)
Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole<i>et al</i>
Authors: Maxime Samson, Sylvain Audia, Nona Janikashvili, Bernard Bonnotte
Journal: Annals of the Rheumatic Diseases (2013)

We have read with interest the recently published paper of Espigol-Frigole et al 1 in which the authors confirmed that interleukin (IL)-17 is highly expressed in giant cell arteritis (GCA) lesions.1–3 They also demonstrated for the first time that IL-17 expression in temporal artery biopsies (TABs) was correlated with a better outcome. Among other interesting results, the identification of Foxp3+IL-17+ T cells by confocal microscopy in TAB made the authors to hypothesize that these cells could be induced regulatory T cells (Treg) that may facilitate the remission of the disease under steroid therapy. …
Recommended Reading from the University of Pennsylvania Pulmonary and Critical Care Fellows
Authors: Christopher T. Dibble, Sarah Lyon, Daniel Dorgan, Joshua Diamond
Journal: American Journal of Respiratory and Critical Care Medicine (2010)

Preclinical research and small case series have suggested that sildenafil may be a safe treatment for idiopathic pulmonary fibrosis (IPF). The IPF Clinical Research Network performed a randomized, double-blind, placebo-controlled study of sildenafil for idiopathic pulmonary fibrosis. Participants (n 5 180) were included if they had advanced disease, defined as diffusing capacity for carbon monoxide (DLCO) of less than 35% of predicted. Exclusion criteria included 6-minute walk distance less than 164 feet, resting oxygen saturation less than 92% on high-flow oxygen, and significant cardiac disease. The study consisted of a 12-week double-blind period followed by a 12-week open-label study. After the initial 12 weeks, there was no difference in the primary endpoint, defined as an increase in 6-minute walk distance of more than 20%, between the study and placebo groups. Sildenafil treatment was associated with statistically significant improvements in DLCO, oxygenation, degree of dyspnea, and quality of life. Serious adverse events were common (z 15%) but equally balanced across groups. Overall, this is a negative study. Although secondary endpoint findings do suggest that sildenafil is safe in patients with severe IPF and may favorably influence physiologic variables and symptoms, more evidence is needed before clinical practice is changed. A significant limitation is the lack of hemodynamic measurements. Future trials should address subsets of patients with IPF, such as those with less advanced IPF or those with significant pulmonary hypertension.
Pancreatic Cancer and Precursor Pancreatic Intraepithelial Neoplasia Lesions Are Devoid of Primary Cilia
Authors: E. Scott Seeley, Catherine Carrière, Tobias Goetze, Daniel S. Longnecker, Murray Korc
Journal: Cancer Research (2009)

Abstract Primary cilia have been proposed to participate in the modulation of growth factor signaling pathways. In this study, we determined that ciliogenesis is suppressed in both pancreatic cancer cells and pancreatic intraepithelial neoplasia (PanIN) lesions in human pancreatic ductal adenocarcinoma (PDAC). Primary cilia were absent in these cells even when not actively proliferating. Cilia were also absent from mouse PanIN cells in three different mouse models of PDAC driven by an endogenous oncogenic Kras allele. Inhibition of Kras effector pathways restored ciliogenesis in a mouse pancreatic cancer cell line, raising the possibility that ciliogenesis may be actively repressed by oncogenic Kras. By contrast, normal duct, islet, and centroacinar cells retained primary cilia in both human and mouse pancreata. Thus, arrested ciliogenesis is a cardinal feature of PDAC and its precursor PanIN lesions, does not require ongoing proliferation, and could potentially be targeted pharmacologically. [Cancer Res 2009;69(2):422–30]
Effects of rapid weight loss on mood and performance among amateur boxers
Authors: C J Hall, A M Lane
Journal: British Journal of Sports Medicine (2001)

Aims —To examine the effects of rapid weight loss on mood and performance among amateur boxers. Methods —Participants were 16 experienced amateur boxers. In stage 1, structured interviews were used to assess the type of strategies that boxers used to reduce weight and the value of performing at their desired weight in terms of performance. In stage 2, boxers completed a 4 × 2 minute (1 minute recovery) circuit training session. Boxers completed the circuit training session on three different occasions with a week between each. The first test was used to familiarise the boxers with the circuit training task; the second and third tasks were at their training weight and championship weight, respectively. Participants were given one week to reduce their body weight to their championship weight using their preferred weight making strategies; boxers reduced their body weight by an average of 5.16% of body weight. Results —Boxers typically lost weight by restricting fluid and food intake in the week leading to competition. Repeated measures multivariate analysis of variance results indicated that rapid weight loss among boxers was associated with poor performance, increased anger, fatigue, and tension, and reduced vigour. Conclusions —Strategies used to make weight by boxers are associated with poor performance and a negative mood profile.
Perioperative Outcomes of Adolescents Undergoing Bariatric Surgery
Authors: Thomas H. Inge, Meg H. Zeller, Todd M. Jenkins, Michael Helmrath, Mary L. Brandt, Marc P. Michalsky, Carroll M. Harmon, Anita Courcoulas, Mary Horlick, Stavra A. Xanthakos, Larry Dolan, Mark Mitsnefes, Sean J. Barnett, Ralph Buncher
Journal: JAMA Pediatrics (2013)

<h3>Importance</h3> Severe obesity in childhood is a major health problem with few effective treatments. Weight-loss surgery (WLS) is being used to treat severely obese adolescents, although with very limited data regarding surgical safety for currently used, minimally invasive procedures. <h3>Objective</h3> To assess the preoperative clinical characteristics and perioperative safety outcomes of severely obese adolescents undergoing WLS. <h3>Design, Setting, and Participants</h3> This prospective, multisite observational study enrolled patients from February 28, 2007, through December 30, 2011. Consecutive patients aged 19 years or younger who were approved to undergo WLS (n = 277) were offered enrollment into the study at 5 academic referral centers in the United States; 13 declined participation and 22 did not undergo surgery after enrollment, thus the final analysis cohort consisted of 242 individuals. There were no withdrawals. <h3>Main Outcomes and Measures</h3> This analysis examined preoperative anthropometrics, comorbid conditions, and major and minor complications occurring within 30 days of operation. All data were collected in a standardized fashion. Reoperations and hospital readmissions were adjudicated by independent reviewers to assess relatedness to the WLS procedure. <h3>Results</h3> The mean (SD) age of participants was 17.1 (1.6) years and the median body mass index (calculated as weight in kilograms divided by height in meters squared) was 50.5. Fifty-one percent demonstrated 4 or more major comorbid conditions. Laparoscopic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, and adjustable gastric banding were performed in 66%, 28%, and 6% of patients, respectively. There were no deaths during the initial hospitalization or within 30 days of operation; major complications (eg, reoperation) were seen in 19 patients (8%). Minor complications (eg, readmission for dehydration) were noted in 36 patients (15%). All reoperations and 85% of readmissions were related to WLS. <h3>Conclusions and Relevance</h3> In this series, adolescents with severe obesity presented with abundant comorbid conditions. We observed a favorable short-term complication profile, supporting the early postoperative safety of WLS in select adolescents. Further longitudinal study of this cohort will permit accurate assessment of long-term outcomes for adolescents undergoing bariatric surgery. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT00474318
Expression of Novel Molecules, MICAL2-PV (MICAL2 Prostate Cancer Variants), Increases with High Gleason Score and Prostate Cancer Progression
Authors: Shingo Ashida, Mutsuo Furihata, Toyomasa Katagiri, Kenji Tamura, Yoshio Anazawa, Hiroki Yoshioka, Tsuneharu Miki, Tomoaki Fujioka, Taro Shuin, Yusuke Nakamura, Hidewaki Nakagawa
Journal: Clinical Cancer Research (2006)

Abstract Purpose: The aim of this study is to identify novel molecular targets for development of novel treatment or diagnostic markers of prostate cancer through genome-wide cDNA microarray analysis of prostate cancer cells purified by laser microdissection. Experimental Design and Results: Here, we identified molecule interacting with CasL-2 prostate cancer variants (MICAL2-PV), novel splicing variants of MICAL2, showing overexpression in prostate cancer cells. Immunohistochemical analysis using an antibody generated specific to MICAL2-PV revealed that MICAL2-PV was expressed in the cytoplasm of cancer cells with various staining patterns and intensities, whereas it was not or hardly detectable in adjacent normal prostate epithelium or prostatic intraepithelial neoplasia. Interestingly, immunohistochemical analysis of 105 prostate cancer specimens on the tissue microarray indicated that MICAL2-PV expression status was strongly correlated with Gleason scores (P &amp;lt; 0.0001) or tumor classification (P &amp;lt; 0.0001). Furthermore, the expression levels of MICAL2-PVs were also concordant to those of c-Met, a marker of tumor progression, with statistical significance (P = 0.0018). To investigate its potential of molecular therapeutic target for prostate cancers, we knocked down endogenous MICAL2-PVs in prostate cancer cells by small interfering RNA, which resulted in the significant reduction of prostate cancer cell viability. Conclusions: Our findings suggest that MICAL2-PV is likely to be involved in cancer progression of prostate cancer and could be a candidate as a novel molecular marker and/or target for treatment of prostate cancers with high Gleason score.